Porcine antibody profiles of 33 Mycoplasma hyopneumoniae fusion proteins from M. hyopneumoniae natural infection but not vaccination
© 2022 The Authors. Veterinary Medicine and Science published by John Wiley & Sons Ltd..
BACKGROUND: Mycoplasma hyopneumoniae, the primary pathogen responsible for porcine enzootic pneumonia, reduces average daily weight gain and causes substantial economic losses to the pig industry worldwide. Vaccination is the most common strategy to control this disease but offers partial protection. Therefore, developing next-generation vaccines by screening protective antigens is crucial.
OBJECTIVES: The aim of this study was to evaluate the antibody response to 33 recombinant proteins in pigs naturally infected with M. hyopneumoniae.
METHODS: The genes encoding 33 (hypothetical) membrane proteins or secretory proteins were ligated into pGEX-6P-1, pGEX-6P-2, pGEX-5X-3 or pGEX-4T-3 vectors and transformed into Escherichia coli BL21(DE3) or E. coli XL-1 Blue to construct recombinant bacteria and to express the recombinant proteins. The recombinant bacteria expressing the target proteins reacted with porcine convalescent sera and negative sera to screen immunodominant proteins by ELISA. Then, recombinant bacteria expressing immunodominant proteins were used to identify the discriminating immunodominant proteins that were recognised by convalescent sera nut not hyperimmune sera.
RESULTS: All recombinant bacteria could express the target recombinant proteins in soluble form. Twenty-one proteins were shown to present immunodominant antigens, and four proteins were not recognised by convalescent sera. Moreover, six proteins were considered discriminating and reacted with convalescent sera but not with hyperimmune sera.
CONCLUSIONS: The identified immunodominant proteins were antigenic and expressed during bacterial infection, suggesting that these proteins, especially those capable of discriminating between sera, can be used to identify protective antigens with the view to develop more effective vaccines against M. hyopneumoniae infection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Veterinary medicine and science - 9(2023), 1 vom: 17. Jan., Seite 203-216 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ning, Yaru [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antigens, Bacterial |
|---|
| Anmerkungen: |
Date Completed 24.01.2023 Date Revised 31.01.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/vms3.1053 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350325995 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350325995 | ||
| 003 | DE-627 | ||
| 005 | 20231226044738.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/vms3.1053 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1167.xml |
| 035 | |a (DE-627)NLM350325995 | ||
| 035 | |a (NLM)36520664 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ning, Yaru |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Porcine antibody profiles of 33 Mycoplasma hyopneumoniae fusion proteins from M. hyopneumoniae natural infection but not vaccination |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.01.2023 | ||
| 500 | |a Date Revised 31.01.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 The Authors. Veterinary Medicine and Science published by John Wiley & Sons Ltd. | ||
| 520 | |a BACKGROUND: Mycoplasma hyopneumoniae, the primary pathogen responsible for porcine enzootic pneumonia, reduces average daily weight gain and causes substantial economic losses to the pig industry worldwide. Vaccination is the most common strategy to control this disease but offers partial protection. Therefore, developing next-generation vaccines by screening protective antigens is crucial | ||
| 520 | |a OBJECTIVES: The aim of this study was to evaluate the antibody response to 33 recombinant proteins in pigs naturally infected with M. hyopneumoniae | ||
| 520 | |a METHODS: The genes encoding 33 (hypothetical) membrane proteins or secretory proteins were ligated into pGEX-6P-1, pGEX-6P-2, pGEX-5X-3 or pGEX-4T-3 vectors and transformed into Escherichia coli BL21(DE3) or E. coli XL-1 Blue to construct recombinant bacteria and to express the recombinant proteins. The recombinant bacteria expressing the target proteins reacted with porcine convalescent sera and negative sera to screen immunodominant proteins by ELISA. Then, recombinant bacteria expressing immunodominant proteins were used to identify the discriminating immunodominant proteins that were recognised by convalescent sera nut not hyperimmune sera | ||
| 520 | |a RESULTS: All recombinant bacteria could express the target recombinant proteins in soluble form. Twenty-one proteins were shown to present immunodominant antigens, and four proteins were not recognised by convalescent sera. Moreover, six proteins were considered discriminating and reacted with convalescent sera but not with hyperimmune sera | ||
| 520 | |a CONCLUSIONS: The identified immunodominant proteins were antigenic and expressed during bacterial infection, suggesting that these proteins, especially those capable of discriminating between sera, can be used to identify protective antigens with the view to develop more effective vaccines against M. hyopneumoniae infection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a ELISA | |
| 650 | 4 | |a GST fusion protein | |
| 650 | 4 | |a convalescent sera | |
| 650 | 4 | |a hyperimmune sera | |
| 650 | 4 | |a immunodominant protein | |
| 650 | 7 | |a Antigens, Bacterial |2 NLM | |
| 650 | 7 | |a Recombinant Proteins |2 NLM | |
| 700 | 1 | |a Yang, Yujiao |e verfasserin |4 aut | |
| 700 | 1 | |a Tian, Yaqin |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yun |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Wenyi |e verfasserin |4 aut | |
| 700 | 1 | |a Wen, Yukang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Yaoqin |e verfasserin |4 aut | |
| 700 | 1 | |a Ding, Honglei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Veterinary medicine and science |d 2015 |g 9(2023), 1 vom: 17. Jan., Seite 203-216 |w (DE-627)NLM262254441 |x 2053-1095 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2023 |g number:1 |g day:17 |g month:01 |g pages:203-216 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/vms3.1053 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2023 |e 1 |b 17 |c 01 |h 203-216 | ||